Aeolus Pharmaceuticals, Inc.

Equities

AOLS

US00765G1094

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 10:44:28 2024-04-11 am EDT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		0.00%	0.00%

2017	Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and First Nine Months Ended June 30, 2017	CI
2017	Aeolus Pharmaceuticals, Inc. Announces Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event	CI

Aeolus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt

December 21, 2014

Aeolus Pharmaceuticals Inc. filed its 10-K on Dec 22, 2014 for the period ending Sep 30, 2014. In this report its auditor, Grant Thornton, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Latest news about Aeolus Pharmaceuticals, Inc.

Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and First Nine Months Ended June 30, 2017	17-08-14	CI
Aeolus Pharmaceuticals, Inc. Announces Fast Track Designation Granted to AEOL 10150 for Treatment of Patients With Lung Acute Radiation Syndrome Following a Radiologial or Nuclear Event	17-06-08	CI
Aeolus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2017	17-05-15	CI
Aeolus Pharmaceuticals, Inc. Initiates Phase 1 Study of AEOL 10150 in Healthy Normal Volunteers	17-02-22	CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2016	16-12-21	CI
Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2016	16-08-15	CI
Aeolus Pharmaceuticals Inc. Announces Unaudited Consolidated Results for the Second Quarter and Six Months Ended March 31, 2016	16-05-16	CI
Aeolus Pharmaceuticals Inc. Announces Removal of FDA Clinical Hold on AEOL 10150	16-02-22	CI
Aeolus Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended December 31, 2015	16-02-17	CI
Aeolus Pharmaceuticals Enters into Definitive Agreements to Raise Gross Proceeds of $6.75 Million in Private Placement Financing	15-12-27	CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2015	15-12-21	CI
Aeolus Pharmaceuticals Inc. announced that it has received $6.75 million in funding from BVF Partners LP and other investors.	15-12-09	CI
Aeolus Pharmaceuticals Inc. announced that it has received $1 million in funding from BVF Partners LP.	15-09-28	CI
Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2015	15-08-17	CI
Barda Exercises $3 Million in Additional Contract Funding for Development of Aeol 10150 as Treatment for Acute Radiation Syndrome	15-06-26	CI
Aeolus Pharmaceuticals Inc. Reports Consolidated Unaudited Earnings Results for the Second Quarter and Six Months Ended March 31, 2015	15-05-15	CI
Aeolus Pharmaceuticals, Inc. Announces Unaudited Consolidated Financial Results for the First Quarter Ended December 31, 2014	15-02-13	CI
Aeolus Pharmaceuticals Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2014	14-12-22	CI
Aeolus Pharmaceuticals Inc. Auditor Raises 'Going Concern' Doubt	14-12-21	CI
Aeolus Pharmaceuticals Inc. Announces Presentation of Efficacy Data for AEOL 10150	14-10-20	CI
Aeolus Announces Results from Study of AEOL 10150 Doubles Survival Rate Against Lung Damage from Radiation Exposure	14-09-04	CI
Aeolus Pharmaceuticals, Inc. Files Investigational New Drug Application With US FDA to Enable Initiation of Human Safety Studies for the Development of AEOL as a Medical Countermeasure against Lung Damage from Radiation Exposure	14-08-20	CI
Aeolus Pharmaceuticals Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014	14-08-15	CI
Aeolus Pharmaceuticals, Inc. Announces Data Demonstrating Efficacy of AEOL 10150 in Animal CEES Model of Mustard Gas Skin Exposure	14-06-18	CI
Aeolus Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended March 31, 2014	14-05-15	CI

Chart Aeolus Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The Company's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AEOLUS PHARMACEUTICALS, INC.	0.00%	152
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research